These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21375483)

  • 1. Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
    Del-Bel E; Padovan-Neto FE; Raisman-Vozari R; Lazzarini M
    Curr Pharm Des; 2011; 17(5):471-88. PubMed ID: 21375483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
    Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
    Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
    Bortolanza M; Cavalcanti-Kiwiatkoski R; Padovan-Neto FE; da-Silva CA; Mitkovski M; Raisman-Vozari R; Del-Bel E
    Neurobiol Dis; 2015 Jan; 73():377-87. PubMed ID: 25447229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
    Dwi Wahyu I; Chiken S; Hasegawa T; Sano H; Nambu A
    J Neurosci; 2021 Mar; 41(12):2668-2683. PubMed ID: 33563724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.
    Novaretti N; Padovan-Neto FE; Tumas V; da-Silva CA; Del Bel EA
    Braz J Med Biol Res; 2010 Nov; 43(11):1047-53. PubMed ID: 21088802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
    Bortolanza M; Bariotto-Dos-Santos KD; Dos-Santos-Pereira M; da-Silva CA; Del-Bel E
    Neurotox Res; 2016 Jul; 30(1):88-100. PubMed ID: 27053252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
    Solís O; Espadas I; Del-Bel EA; Moratalla R
    Neurobiol Dis; 2015 Jan; 73():49-59. PubMed ID: 25281315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
    Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
    Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
    Takuma K; Tanaka T; Takahashi T; Hiramatsu N; Ota Y; Ago Y; Matsuda T
    Eur J Pharmacol; 2012 May; 683(1-3):166-73. PubMed ID: 22449381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiology of L-dopa-induced abnormal involuntary movements.
    Agid Y; Bonnet AM; Ruberg M; Javoy-Agid F
    Psychopharmacology Suppl; 1985; 2():145-59. PubMed ID: 2987904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide, a new player in L-DOPA-induced dyskinesia?
    Del-Bel E; Padovan-Neto FE; Bortolanza M; Tumas V; Aguiar AS; Raisman-Vozari R; Prediger RD
    Front Biosci (Elite Ed); 2015 Jan; 7(1):168-92. PubMed ID: 25553372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
    Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.